Patents by Inventor Cameron DURRANT

Cameron DURRANT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210322547
    Abstract: Methods for neutralizing and/or removing human GM-CSF in a subject in need thereof, comprising administering to the subject CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells) are provided. Also provided are methods for GM-CSF gene inactivation or GM-CSF knockout (KO) in a cell comprising targeted genome editing or GM-CSF gene silencing. Methods for preventing/treating immunotherapy-related toxicity, comprising administering to the subject CAR-T cells having a GM-CSF gene inactivation or GM-CSF knockout (GM-CSFk/o CAR-T cells), wherein the GM-CSF gene is inactivated or knocked out and/or a recombinant GM-CSF antagonist are provided. Methods for reducing a level of a cytokine or chemokine other than GM-CSF in a subject having immunotherapy-related toxicity comprising administering to the subject a recombinant hGM-CSF antagonist are provided.
    Type: Application
    Filed: April 19, 2021
    Publication date: October 21, 2021
    Applicant: HUMANIGEN, INC.
    Inventors: Cameron Durrant, Dale Chappell
  • Publication number: 20210309733
    Abstract: The present invention provides methods for treating a subject infected with 2019 coronavirus (SARS-CoV-2) comprising administering to the subject a therapeutically effective amount of a GM-CSF antagonist or a therapeutically effective amount of a GM-CSF antagonist and a second drug, including an anti-viral agent, an anti-SARS-CoV-2 vaccine, and serum containing human polyclonal antibodies to SARS-CoV-2.
    Type: Application
    Filed: March 29, 2021
    Publication date: October 7, 2021
    Applicant: HUMANIGEN, INC.
    Inventors: Cameron DURRANT, Dale CHAPPELL
  • Patent number: 11130805
    Abstract: Methods for reducing blood-brain barrier disruption in a subject treated with immunotherapy, the method comprising administering a recombinant GM-CSF antagonist to the subject. Methods for preserving blood-brain barrier integrity in a subject treated with immunotherapy, the method comprising administering a recombinant hGM-CSF antagonist to the subject. Methods for decreasing or preventing CAR-T cell therapy-induced neuroinflammation in a subject in need thereof, the method comprising administering a recombinant GM-CSF antagonist to the subject. Methods for preventing or reducing blood-brain barrier disruption in a subject treated with immunotherapy, the method comprising administering CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells) to the subject.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: September 28, 2021
    Assignee: HUMANIGEN, INC.
    Inventors: Cameron Durrant, Dale Chappell
  • Publication number: 20210290677
    Abstract: Methods for neutralizing and/or removing human GM-CSF in a subject in need thereof, comprising administering to the subject CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells) are provided. Also provided are methods for GM-CSF gene inactivation or GM-CSF knockout (KO) in a cell comprising targeted genome editing or GM-CSF gene silencing. Methods for preventing/treating immunotherapy-related toxicity, comprising administering to the subject CAR-T cells having a GM-CSF gene inactivation or GM-CSF knockout (GM-CSFk/o CAR-T cells), wherein the GM-CSF gene is inactivated or knocked out and/or or a recombinant GM-CSF antagonist are provided. Methods for reducing a level of a cytokine or chemokine other than GM-CSF in a subject having immunotherapy-related toxicity comprising administering to the subject a recombinant hGM-CSF antagonist are provided.
    Type: Application
    Filed: September 10, 2019
    Publication date: September 23, 2021
    Applicant: HUMANIGEN, INC.
    Inventors: Cameron DURRANT, Dale CHAPPELL
  • Publication number: 20210284714
    Abstract: This document provides methods and materials involved in treating cancer. For example, chimeric antigen receptor T cells having reduced levels of GM-CSF are provided. Also provided as methods for making and using chimeric antigen receptor T cells having reduced levels of GM-CSF.
    Type: Application
    Filed: March 22, 2021
    Publication date: September 16, 2021
    Applicants: HUMANIGEN, INC., MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Cameron DURRANT, Dale CHAPPELL, Saad J. KENDERIAN, Michelle J. COX, Reona SAKEMURA
  • Publication number: 20210269518
    Abstract: Methods for reducing relapse rate or preventing occurrence of tumor relapse in a subject treated with immunotherapy, in an absence of an incidence of immunotherapy-related toxicity or in a presence of immunotherapy-related toxicity. Methods for reducing a level of a cytokine or chemokine other than GM-CSF in a subject having an incidence of immunotherapy-related toxicity, the methods comprising administering a recombinant GM-CSF antagonist to the subject. Methods for treating or preventing immunotherapy-related toxicity in a subject, the methods comprising administering to the subject chimeric antigen receptor-expressing T-cells (CAR-T cells), the CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells), and a recombinant hGM-CSF antagonist.
    Type: Application
    Filed: January 16, 2021
    Publication date: September 2, 2021
    Applicant: HUMANIGEN, INC.
    Inventors: Cameron DURRANT, Dale Chappell
  • Publication number: 20210246215
    Abstract: This invention provides chimeric antigen receptors (CARs) targeting human EphA3 and dual targeting CARs that bind to human EphA3 and to human mutant epidermal growth factor receptor variant III (EGFRvIII). This invention also relates to CAR-T cells comprising the provided CARs or the dual targeting CARs. Methods for treating a solid tumor cancer by administering the CARs are provided.
    Type: Application
    Filed: November 9, 2020
    Publication date: August 12, 2021
    Applicants: HUMANIGEN, INC., MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Cameron DURRANT, Dale CHAPPELL, Saad J. KENDERIAN
  • Publication number: 20210230262
    Abstract: Methods for reducing relapse rate or preventing occurrence of tumor relapse in a subject treated with immunotherapy, in an absence of an incidence of immunotherapy-related toxicity or in a presence of immunotherapy-related toxicity. Methods for reducing a level of a cytokine or chemokine other than GM-CSF in a subject having an incidence of immunotherapy-related toxicity, the methods comprising administering a recombinant GM-CSF antagonist to the subject. Methods for treating or preventing immunotherapy-related toxicity in a subject, the methods comprising administering to the subject chimeric antigen receptor-expressing T-cells (CAR-T cells), the CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells), and a recombinant hGM-CSF antagonist.
    Type: Application
    Filed: January 27, 2021
    Publication date: July 29, 2021
    Applicant: HUMANIGEN, INC.
    Inventors: Cameron DURRANT, Dale CHAPPELL
  • Publication number: 20210130488
    Abstract: Methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject, the method comprising a step of administering a recombinant hGM-CSF antagonist to the subject, wherein said administering inhibits or reduces the incidence or the severity of immunotherapy-related toxicity in said subject, are provided. An hGM-CSF antagonist for use in methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject also are provided.
    Type: Application
    Filed: November 13, 2020
    Publication date: May 6, 2021
    Applicant: HUMANIGEN, INC.
    Inventors: Cameron DURRANT, Dale CHAPPELL
  • Patent number: 10927168
    Abstract: Methods for reducing relapse rate or preventing occurrence of tumor relapse in a subject treated with immunotherapy, in an absence of an incidence of immunotherapy-related toxicity or in a presence of immunotherapy-related toxicity. Methods for reducing a level of a cytokine or chemokine other than GM-CSF in a subject having an incidence of immunotherapy-related toxicity, the methods comprising administering a recombinant GM-CSF antagonist to the subject. Methods for treating or preventing immunotherapy-related toxicity in a subject, the methods comprising administering to the subject chimeric antigen receptor-expressing T-cells (CAR-T cells), the CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells), and a recombinant hGM-CSF antagonist.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: February 23, 2021
    Assignee: HUMANICEN, INC.
    Inventors: Cameron Durrant, Dale Chappell
  • Publication number: 20210046038
    Abstract: This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED. This invention further encompasses a method of treating a subject in need of such treatment comprising administering a therapeutically effective amount of A19-144 or A2-73 in conjunction with any therapeutically effective amount of an AED.
    Type: Application
    Filed: October 26, 2020
    Publication date: February 18, 2021
    Applicant: ANAVEX LIFE SCIENCES CORP.
    Inventors: Christopher U. Missling, Cameron Durrant
  • Patent number: 10899831
    Abstract: Methods for reducing relapse rate or preventing occurrence of tumor relapse in a subject treated with immunotherapy, in an absence of an incidence of immunotherapy-related toxicity or in a presence of immunotherapy-related toxicity. Methods for reducing a level of a cytokine or chemokine other than GM-CSF in a subject having an incidence of immunotherapy-related toxicity, the methods comprising administering a recombinant GM-CSF antagonist to the subject. Methods for treating or preventing immunotherapy-related toxicity in a subject, the methods comprising administering to the subject chimeric antigen receptor-expressing T-cells (CAR-T cells), the CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells), and a recombinant hGM-CSF antagonist.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: January 26, 2021
    Assignee: HUMANIGEN, INC.
    Inventors: Cameron Durrant, Dale Chappell
  • Patent number: 10870703
    Abstract: Methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject, the method comprising a step of administering a recombinant hGM-CSF antagonist to the subject, wherein said administering inhibits or reduces the incidence or the severity of immunotherapy-related toxicity in said subject, are provided. An hGM-CSF antagonist for use in methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject also are provided.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: December 22, 2020
    Assignee: HUMANIGEN, INC.
    Inventors: Cameron Durrant, Dale Chappell
  • Publication number: 20200354443
    Abstract: Methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject, the method comprising a step of administering a recombinant hGMCSF antagonist to the subject, wherein said administering inhibits or reduces the incidence or the severity of immunotherapy-related toxicity in said subject, are provided. An hGMCSF antagonist for use in methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject also are provided.
    Type: Application
    Filed: October 2, 2018
    Publication date: November 12, 2020
    Applicant: HUMANIGEN, INC.
    Inventors: Cameron DURRANT, Dale CHAPPELL
  • Patent number: 10813907
    Abstract: This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED. This invention further encompasses a method of treating a subject in need of such treatment comprising administering a therapeutically effective amount of A19-144 or A2-73 in conjunction with an therapeutically effective amount of an AED.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: October 27, 2020
    Assignee: ANAVEX LIFE SCINCES CORP.
    Inventors: Christopher U. Missling, Cameron Durrant
  • Publication number: 20200038365
    Abstract: This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED. This invention further encompasses a method of treating a subject in need of such treatment comprising administering a therapeutically effective amount of A19-144 or A2-73 in conjunction with an therapeutically effective amount of an AED.
    Type: Application
    Filed: October 14, 2019
    Publication date: February 6, 2020
    Applicant: ANAVEX LIFE SCIENCES CORP.
    Inventors: Christopher U. Missling, Cameron Durrant
  • Publication number: 20190338023
    Abstract: Methods for reducing relapse rate or preventing occurrence of tumor relapse in a subject treated with immunotherapy, in an absence of an incidence of immunotherapy-related toxicity or in a presence of immunotherapy-related toxicity. Methods for reducing a level of a cytokine or chemokine other than GM-CSF in a subject having an incidence of immunotherapy-related toxicity, the methods comprising administering a recombinant GM-CSF antagonist to the subject. Methods for treating or preventing immunotherapy-related toxicity in a subject, the methods comprising administering to the subject chimeric antigen receptor-expressing T-cells (CAR-T cells), the CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells), and a recombinant hGM-CSF antagonist.
    Type: Application
    Filed: January 15, 2019
    Publication date: November 7, 2019
    Applicant: HUMANIGEN, INC.
    Inventors: Cameron DURRANT, Dale Chappell
  • Publication number: 20190322735
    Abstract: Methods for reducing blood-brain barrier disruption in a subject treated with immunotherapy, the method comprising administering a recombinant GM-CSF antagonist to the subject. Methods for preserving blood-brain barrier integrity in a subject treated with immunotherapy, the method comprising administering a recombinant hGM-CSF antagonist to the subject. Methods for decreasing or preventing CAR-T cell therapy-induced neuroinflammation in a subject in need thereof, the method comprising administering a recombinant GM-CSF antagonist to the subject. Methods for preventing or reducing blood-brain barrier disruption in a subject treated with immunotherapy, the method comprising administering CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells) to the subject.
    Type: Application
    Filed: February 22, 2019
    Publication date: October 24, 2019
    Applicant: HUMANIGEN, INC.
    Inventors: Cameron Durrant, Dale CHAPPELL
  • Publication number: 20190284271
    Abstract: Methods for reducing relapse rate or preventing occurrence of tumor relapse in a subject treated with immunotherapy, in an absence of an incidence of immunotherapy-related toxicity or in a presence of immunotherapy-related toxicity. Methods for reducing a level of a cytokine or chemokine other than GM-CSF in a subject having an incidence of immunotherapy-related toxicity, the methods comprising administering a recombinant GM-CSF antagonist to the subject. Methods for treating or preventing immunotherapy-related toxicity in a subject, the methods comprising administering to the subject chimeric antigen receptor-expressing T-cells (CAR-T cells), the CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells), and a recombinant hGM-CSF antagonist.
    Type: Application
    Filed: November 29, 2018
    Publication date: September 19, 2019
    Applicant: HUMANIGEN, INC.
    Inventors: Cameron DURRANT, Dale Chappell
  • Publication number: 20190194343
    Abstract: Methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject, the method comprising a step of administering a recombinant hGM-CSF antagonist to the subject, wherein said administering inhibits or reduces the incidence or the severity of immunotherapy-related toxicity in said subject, are provided. An hGM-CSF antagonist for use in methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject also are provided.
    Type: Application
    Filed: October 2, 2018
    Publication date: June 27, 2019
    Applicant: Humanigen, Inc.
    Inventors: Cameron DURRANT, Dale Chappell